Tyrosine kinase inhibitors in the treatment of prostate cancer: taking the next step in clinical development
Authors:
- Ravi A MadanRMRavi A Madan
- William L DahutWDWilliam L Dahut
- 7 October 2014
- journal article
- review article
- Published by Taylor & Francis in Expert Opinion on Emerging Drugs
- Vol. 19 (4) , 459-470
Abstract
Prostate cancer (PCa) is the most frequently diagnosed, non-cutaneous malignancy in Western countries. Until recently, few therapeutic options were available for patients with advanced PCa. Although these treatments may delay progression of disease, none are curative. Therefore, research continues to investigate other treatments for advanced PCa. Tyrosine kinase inhibitors (TKIs) have been extensively studied as a treatment for multiple malignancies and may represent an additional strategy. In addition to limiting cellular proliferation and metastasis, there is also growing interest in using these treatments to impact the bone microenvironment and reduce associated morbidity from PCa. Several TKIs have been evaluated in the preclinical setting in advanced PCa. Targets reviewed include the epidermal growth factor family, VEGF receptor, c-Src family kinases, platelet-derived growth factor and c-Met. Despite strong biological rationale for the use of TKIs therapy for the treatment of PCa, Phase III clinical trials have produced disappointing results. As TKI strategies move forward, the failures of past trials need to be better understood. New approaches with these treatments will also have to take into account modern anti-androgens and a treatment landscape that now includes immunotherapy.Keywords
This publication has 96 references indexed in Scilit:
- Increased Survival with Enzalutamide in Prostate Cancer after ChemotherapyNew England Journal of Medicine, 2012
- The mutational landscape of lethal castration-resistant prostate cancerNature, 2012
- Contemporary Role of Androgen Deprivation Therapy for Prostate CancerEuropean Urology, 2012
- Consequence of dose scheduling of sunitinib on host immune response elements and vaccine combination therapyInternational Journal of Cancer, 2011
- Sipuleucel-T Immunotherapy for Castration-Resistant Prostate CancerNew England Journal of Medicine, 2010
- Cell Signaling by Receptor Tyrosine KinasesCell, 2010
- Dasatinib inhibits site-specific tyrosine phosphorylation of androgen receptor by Ack1 and Src kinasesOncogene, 2010
- Dasatinib inhibits the growth of prostate cancer in bone and provides additional protection from osteolysisBritish Journal of Cancer, 2009
- The ErbB kinase domain: Structural perspectives into kinase activation and inhibitionExperimental Cell Research, 2009
- Immunological aspects of cancer chemotherapyNature Reviews Immunology, 2008